Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ912 in early Alzheimer's disease
NL-OMON44623Phase 2Active, not recruiting
- Sponsor
- Vivoryon Therapeutics N.V.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing PQ912 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Mar 2015; status: active, not recruiting.
02
Drugs
varoglutamstat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON44623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44623.